Champions Oncology, Inc. (CSBR): Revenue
$59.42M
Year ended 2026-04-30
$60.66M
Trailing 12 months to 2026-07-31
+3.3%
3-year compound annual growth
+7.7%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $59.42M | +4.4% | 2026-07-27, From 2025-05-01 |
| 2025-04-30 | $56.94M | +13.5% | 2026-07-27, From 2024-05-01 |
| 2024-04-30 | $50.16M | -6.9% | 2025-07-23, From 2023-05-01 |
| 2023-04-30 | $53.87M | +9.7% | 2024-07-19, From 2022-05-01 |
| 2022-04-30 | $49.11M | +19.7% | 2023-07-24, From 2021-05-01 |
| 2021-04-30 | $41.04M | +27.8% | 2022-07-22, From 2020-05-01 |
| 2020-04-30 | $32.12M | +18.7% | 2021-07-26, From 2019-05-01 |
| 2019-04-30 | $27.07M | +33.7% | 2020-07-28, From 2018-05-01 |
| 2018-04-30 | $20.24M | n/a | 2019-07-29, From 2017-05-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $59.42M | +4.4% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $53.43M | +110.5% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $52.74M | -1.2% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $68.56M | -7.6% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $70.00M | n/a |
| Compugen Ltd (CGEN) | 2025-12-31 | $72.76M | +161.1% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $74.68M | +26.9% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $75.39M | +644.9% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $44.64M | -6.1% |
Compare CSBR, IVVD, PLX, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗